Trends in immunotherapy approach for oral melanoma (OM) in dog
Article Sidebar
Published:
Oct 26, 2018
Keywords:
oral melanoma (OM) immunotherapy DNA vaccine chimerised anti-PD-L1 monoclonal antibody
Main Article Content
Abstract
Oral melanoma (OM) in dog is occurred by dramatically increasing of melanocytes, the melanin producing cells, where located in the epidermis, dermis, mucous membrane, and ocular areas. Mostly of OM are found in the oral cavity of dogs and frequently spreads to the adjacent organs, especially mandible. OM often found in old dogs 8-11 years old or black hair and black skin types. The OM therapeutic approaches include surgery, radiation therapy and chemotherapy. However, recent advanced molecular knowledge has altered and focused on new targeted therapy using stimulating antibodies such as immunotherapy. Immunotherapy by vaccination with tyrosinase DNA vaccine is a new treatment that introduces cancer liked antigen into dog’s cell to stimulate dog’s immune system for potentially able to destroy cancer cells. Moreover, antibodies against programmed death 1 (PD-1) and PD-ligand 1 (PD-L1) have been developed to block PD-1/PD-L1 and stimulate T cell activity which caused T cell to secrete cytokines or chemokines. This review focuses on the novel therapy treatment of OM by using specific antibodies that has been verified to be benefit to patients in the later stages of cancer with pulmonary metastasis.
Article Details
Section
Review articles
References
Bergman, P.J., McKnight, J., Novosad, A., Charney, S., Farrelly, J., Craft, D., Wulderk, M., Jeffers, Y., Sadelain, M., Hohenhaus, A.E., Segal, N., Gregor, P., Engelhorn, M., Riviere, I., Houghton, A.N. and Wolchok J.D. 2003. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research 9(4), 1284-1290.
Bergman, P.J. 2007. Canine oral melanoma. Clinical Techniques in Small Animal Practice 22(2), 55-60.
Blanchard, T., Srivastava, P.K. and Duan F. 2013.Vaccines against advanced melanoma. Clinics in Dermatology 31(2), 179-190.
Boria, P.A., Murry, D.J., Bennett, P.F., Glickman, N.W., Snyder, P.W., Merkel, B.L., Schlittler, D.L., Mutsaers, A.J., Thomas, R.M. and Knapp, D.W. 2004. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224(3), 388-394.
Brockley, L.K., Cooper, M.A., Bennett, P.F. 2013. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal 61(1), 25-31.
Dobson, J.M. 2013. Breed-predispositions to cancer in pedigree dogs. ISRN Veterinary Science 1-23.
Finocchiaro, L.M., Fondello, C., Gil-Cardeza M.L., Rossi U.A., Villaverde M.S., Riveros M.D. and Glikin G.C. 2015. Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Human Gene Therapy 26(6), 367-376.
Freeman, K.P., Hahn, K.A., Harris, F.D. and King, G.K. 2003. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). Journal of Veterinary Internal Medicine 17(1), 96-101.
Gillard, M., Cadieu, E., De Brito, C., Abadie, J., Vergier, B., Devauchelle, P., Degorce, F., Dréano, S., Primot, A., Dorso, L., Lagadic, M., Galibert, F., Hédan, B., Galibert, M.-D. and André, C. 2014. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell & Melanoma Research 27(1), 90-102.
Hartley, G., Faulhaber, E., Caldwell, A., Coy, J., Kurihara, J., Guth, A., Regan, D. and Dow, S. 2017. Immune regulation of canine tumour and macrophage PD-L1 expression. Veterinary and Comparative Oncology 15(2), 534-549.
Kawabe, M., Mori, T., Ito, Y., Murakami, M., Sakai, H., Yanai, T. and Maruo K. 2015. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). Journal of the American Veterinary Medical Association 247(10), 1146-1153.
Lee, C., Collichio, F., Ollila, D. and Moschos, S. 2013. Historical review of melanoma treatment and outcomes. Clinics in Dermatology 31(2), 141-147.
Liao, J.C.F., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., Houghton A.N. and Bergman P.J. 2006. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunity 6(1), 8.
MacEwen, E.G.; Patnaik, A.K.; Harvey, H.J.; Hayes, A.A.; Matus, R. 1986. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investigation 4, 397-402.
Maekawa, N., Konnai, S., Ikebuchi, R., Okagawa, T., Adachi, M., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Murata, S. and Ohashi, K. 2014. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One 9(6), e98415.
Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Kato, Y., Murata, S. and Ohashi, K. 2016. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS One 11(6), e0157176.
Maekawa, N., Konnai, S., Takagi, S., Kagawa, Y., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Deguchi, T., Nakajima, C., Kato, Y., Yamamoto, K., Uemura, H., Suzuki, Y., Murata, S. and Ohashi, K. 2017. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports 7(1), 8951.
Manley, C.A., Leibman, N.F., Wolchok, J.D., Riviere, I.C., Bartido, S., Craft, D.M. and Bergman, P.J. 2011. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine 25(1), 94-99.
McLean, J.L. and Lobetti R.G. 2015. Use of the melanoma vaccine in 38 dogs: The South African experience. Journal of the South African Veterinary Association 86(1), 1-4.
Modiano, J.F., Ritt, M.G. and Wojcieszyn, J. 1999. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 13(3), 163-174.
Nishiya, A.T., Massoco, C.O., Felizzola, C.R., Perlmann, E., Batschinski, K., Tedardi, M.V., Garcia, J.S., Mendonça, P.P., Teixeira, T.F. and Zaidan Dagli, M.L. 2016. Comparative aspects of canine melanoma. Veterinary Sciences 3(1), 7.
Ottnod, J.M., Smedley R.C., Walshaw R., Hauptman J.G., Kiupel M. and Obradovich, J.E.. 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and Comparative Oncology 11(3), 219-229.
Riccardo, F., Iussich, S., Maniscalco, L., Mayayo, S.L, La Rosa, G., Arigoni, M., De Maria, R., Gattino, F., Lanzardo, S., Lardone, E., Martano, M., Morello, E., Prestigio, S., Fiore, A., Quaglino, E., Zabarino, S., Ferrone, S., Buracco, P. and Cavallo, F. 2014. CSPG4-Specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research 20(14), 3753-3762.
Teixeira, T.F., Silva, T.C.D., Cogliati, B., Nagamine, M.K., and Dagli, M.L.Z. 2010. Retrospective study of melanocytic neoplasms in dogs and cats. Brazilian Journal of Veterinary Pathology 3, 100-104.
Teixeira, T.F., Gentile, L.B., Da Silva, T.C., Mennecier, G., Chaible, L.M., Cogliati, B., Roman, M.A., Gioso, M.A. and Dagli, M.L. 2014. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas. Veterinary Research Communications 38(1), 29-38.
Topalian, S.L., Hodi F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M. and Sznol, M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 366(26), 2443-2454.
Treggiari, E., Grant, J.P. and North S.M. 2016. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. The Journal of Veterinary Medical Science 78(5), 845-850.
Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G.A., Elders, R., Doyle, R., Taylor, A. and Murphy S. 2017. Use of Oncept melanoma vaccine in 69canine oral malignant melanomas in the UK. Journal of Small Animal Practice 58(1), 10-16.
Wong, R.M., Scotland, R.R., Lau, R.L., Wang, C., Korman, A.J., Kast, W.M. and Weber, J.S. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. International Immunology 19(10), 1223-1234.
Zitvogel, L. and Kroemer, G. 2012. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223-1225.
Bergman, P.J. 2007. Canine oral melanoma. Clinical Techniques in Small Animal Practice 22(2), 55-60.
Blanchard, T., Srivastava, P.K. and Duan F. 2013.Vaccines against advanced melanoma. Clinics in Dermatology 31(2), 179-190.
Boria, P.A., Murry, D.J., Bennett, P.F., Glickman, N.W., Snyder, P.W., Merkel, B.L., Schlittler, D.L., Mutsaers, A.J., Thomas, R.M. and Knapp, D.W. 2004. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. Journal of the American Veterinary Medical Association 224(3), 388-394.
Brockley, L.K., Cooper, M.A., Bennett, P.F. 2013. Malignant melanoma in 63 dogs (2001–2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal 61(1), 25-31.
Dobson, J.M. 2013. Breed-predispositions to cancer in pedigree dogs. ISRN Veterinary Science 1-23.
Finocchiaro, L.M., Fondello, C., Gil-Cardeza M.L., Rossi U.A., Villaverde M.S., Riveros M.D. and Glikin G.C. 2015. Cytokine-enhanced vaccine and interferon-β plus suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Human Gene Therapy 26(6), 367-376.
Freeman, K.P., Hahn, K.A., Harris, F.D. and King, G.K. 2003. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). Journal of Veterinary Internal Medicine 17(1), 96-101.
Gillard, M., Cadieu, E., De Brito, C., Abadie, J., Vergier, B., Devauchelle, P., Degorce, F., Dréano, S., Primot, A., Dorso, L., Lagadic, M., Galibert, F., Hédan, B., Galibert, M.-D. and André, C. 2014. Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell & Melanoma Research 27(1), 90-102.
Hartley, G., Faulhaber, E., Caldwell, A., Coy, J., Kurihara, J., Guth, A., Regan, D. and Dow, S. 2017. Immune regulation of canine tumour and macrophage PD-L1 expression. Veterinary and Comparative Oncology 15(2), 534-549.
Kawabe, M., Mori, T., Ito, Y., Murakami, M., Sakai, H., Yanai, T. and Maruo K. 2015. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006-2012). Journal of the American Veterinary Medical Association 247(10), 1146-1153.
Lee, C., Collichio, F., Ollila, D. and Moschos, S. 2013. Historical review of melanoma treatment and outcomes. Clinics in Dermatology 31(2), 141-147.
Liao, J.C.F., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., Houghton A.N. and Bergman P.J. 2006. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunity 6(1), 8.
MacEwen, E.G.; Patnaik, A.K.; Harvey, H.J.; Hayes, A.A.; Matus, R. 1986. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investigation 4, 397-402.
Maekawa, N., Konnai, S., Ikebuchi, R., Okagawa, T., Adachi, M., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Murata, S. and Ohashi, K. 2014. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS One 9(6), e98415.
Maekawa, N., Konnai, S., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Takagi, S., Kagawa, Y., Nakajima, C., Suzuki, Y., Kato, Y., Murata, S. and Ohashi, K. 2016. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS One 11(6), e0157176.
Maekawa, N., Konnai, S., Takagi, S., Kagawa, Y., Okagawa, T., Nishimori, A., Ikebuchi, R., Izumi, Y., Deguchi, T., Nakajima, C., Kato, Y., Yamamoto, K., Uemura, H., Suzuki, Y., Murata, S. and Ohashi, K. 2017. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Scientific Reports 7(1), 8951.
Manley, C.A., Leibman, N.F., Wolchok, J.D., Riviere, I.C., Bartido, S., Craft, D.M. and Bergman, P.J. 2011. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine 25(1), 94-99.
McLean, J.L. and Lobetti R.G. 2015. Use of the melanoma vaccine in 38 dogs: The South African experience. Journal of the South African Veterinary Association 86(1), 1-4.
Modiano, J.F., Ritt, M.G. and Wojcieszyn, J. 1999. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 13(3), 163-174.
Nishiya, A.T., Massoco, C.O., Felizzola, C.R., Perlmann, E., Batschinski, K., Tedardi, M.V., Garcia, J.S., Mendonça, P.P., Teixeira, T.F. and Zaidan Dagli, M.L. 2016. Comparative aspects of canine melanoma. Veterinary Sciences 3(1), 7.
Ottnod, J.M., Smedley R.C., Walshaw R., Hauptman J.G., Kiupel M. and Obradovich, J.E.. 2013. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and Comparative Oncology 11(3), 219-229.
Riccardo, F., Iussich, S., Maniscalco, L., Mayayo, S.L, La Rosa, G., Arigoni, M., De Maria, R., Gattino, F., Lanzardo, S., Lardone, E., Martano, M., Morello, E., Prestigio, S., Fiore, A., Quaglino, E., Zabarino, S., Ferrone, S., Buracco, P. and Cavallo, F. 2014. CSPG4-Specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clinical Cancer Research 20(14), 3753-3762.
Teixeira, T.F., Silva, T.C.D., Cogliati, B., Nagamine, M.K., and Dagli, M.L.Z. 2010. Retrospective study of melanocytic neoplasms in dogs and cats. Brazilian Journal of Veterinary Pathology 3, 100-104.
Teixeira, T.F., Gentile, L.B., Da Silva, T.C., Mennecier, G., Chaible, L.M., Cogliati, B., Roman, M.A., Gioso, M.A. and Dagli, M.L. 2014. Cell proliferation and expression of connexins differ in melanotic and amelanotic canine oral melanomas. Veterinary Research Communications 38(1), 29-38.
Topalian, S.L., Hodi F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M. and Sznol, M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine 366(26), 2443-2454.
Treggiari, E., Grant, J.P. and North S.M. 2016. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. The Journal of Veterinary Medical Science 78(5), 845-850.
Verganti, S., Berlato, D., Blackwood, L., Amores-Fuster, I., Polton, G.A., Elders, R., Doyle, R., Taylor, A. and Murphy S. 2017. Use of Oncept melanoma vaccine in 69canine oral malignant melanomas in the UK. Journal of Small Animal Practice 58(1), 10-16.
Wong, R.M., Scotland, R.R., Lau, R.L., Wang, C., Korman, A.J., Kast, W.M. and Weber, J.S. 2007. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. International Immunology 19(10), 1223-1234.
Zitvogel, L. and Kroemer, G. 2012. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223-1225.